盐酸普拉克索添加治疗帕金森病的临床疗效及对视觉诱发电位P100潜伏期的影响

Efficacy of pramipexole hydrochloride combined with Madopar in treatment of Parkinson’s disease and its impacts on P100 latency of visual evoked potential

摘要:

目的 探讨盐酸普拉克索联合多巴丝肼片治疗帕金森病（PD）的临床疗效及对视觉诱发电位P100潜伏期的影响。方法 选择2014年3月至2016年4月收治的PD患者60例为研究对象，将60例患者分为对照组（28例）和观察组（32例）。对照组予以多巴丝肼片治疗，观察组在多巴丝肼片基础上联合盐酸普拉克索，共治疗12周。两组患者治疗前及治疗后均采用PD评分量表第III部分（UPDRS III）进行评分，比较治疗疗效。两组患者在治疗前及治疗12周后行视觉诱发电位检查，观察P100潜伏期情况。结果 观察组治疗的显效率（71.88%）和总有效率（90.63%）明显高于对照组（39.29%和64.29%），差异有统计学意义（P < 0.05，P < 0.01）。治疗12周后UPDRS评分，观察组（24.21±12.12）明显低于对照组（16.14±10.12），差异有统计学意义（P<0.05）。两组患者治疗前P100潜伏期均明显延长，两组之间无显著差异（P>0.05）。治疗12周后，观察组P100潜伏期较治疗前显著缩短（P<0.05）；对照组P100潜伏期较治疗前无变化（P>0.05）。结论 盐酸普拉克索联合多巴丝肼片治疗帕金森病，可显著改善患者运动症状，且可以显著缩短P100潜伏期。

Abstract:

Objective To investigate the efficacy of pramipexole hydrochloride combined with Madopar in the treatment of Parkinson’s disease (PD) and its impacts on P100 latency of visual evoked potential (VEP).Methods Sixty patients with PD who were admitted to our hospital from March 2014 to April 2016 were divided into control group (n=28) and observation group (n=32). The control group was treated with Madopar for 12 weeks, while the observation group was given Madopar combined with pramipexole hydrochloride for 12 weeks. PD Rating Scale Part III (UPDRS III) was used to score the two groups before and after treatment. Treatment outcomes were compared between the two groups. P100 latency was evaluated by VEP examinations before treatment and after 12 weeks of treatment.Results The marked and overall response rates were significantly higher in the observation group than in the control group (71.88% vs. 39.29%, P < 0.05; 90.63% vs. 64.29%, P < 0.01). After 12 weeks of treatment, the observation group had a significantly lower UPDRS score than the control group (16.14±10.12 vs. 24.21±12.12, P<0.05). Both groups had substantially prolonged P100 latency before treatment. However, there was no significant difference between the two groups (P>0.05). After 12 weeks of treatment, the observation group had a significantly reduced P100 latency (P<0.05), while there was no significant difference in P100 latency before and after treatment in the control group.Conclusions Pramipexole hydrochloride combined with Madopar can significantly improve patients' motor symptoms and shorten P100 latency in the treatment of Parkinson’s disease.